Preparation of indapamide slow-release pellets

Advances in Therapy

Volumn 21, Issue 4, 2004, Pages 238-246

  Jia, Wei ^a   Qiu, Mingfeng ^a   Sun, Xia ^a   Qiu, Yungping ^b   Su, Mingming ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Coating; Eudragit RS100; Indapamide; Slow release formulations

Indexed keywords

EUDRAGIT; EUDRAGIT RS; INDAPAMIDE;

ARTICLE; DISSOLUTION; DRUG COATING; DRUG FORMULATION; DRUG PELLET; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; OPTIMAL DRUG DOSE; SCALE UP; SLOW RELEASE FORMULATION;

EID: 8744309957     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850156     Document Type: Article

References (9)

1. Asmar R, Guez D, Malbezin M, Brault Y, et al. Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study. Arch Mal Coeur Vaiss. 1995; 88:1083-1087.
2. Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998;16:1677-1684.
3. Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension. Drugs. 2000;59:27-40.
4. Sancin P, Caputo O, Cavallari C, et al. Effects of ultrasound-assisted compaction on ketoprofen/ Eudragit RS100 mixtures. Euro J Pharm Sci. 1999;7:207-213.
5. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53-61.
6. Süslü I, Altinöz S. Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms. J Pharm Biomed Anal. 2002;30:357-364.
7. Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int J Pharm. 1997;154:49-57.
8. Kachrimanis K, Ktistis G, Malamataris S. Crystallisation conditions and physicomechanical properties of ibuprofen-Eudragit® RS100 spherical crystal agglomerates prepared by the solvent-change technique. Int J Pharm. 1998;173:61-74.
9. Ketan A, Mehta MS, Kislalioglu W, et al. Release performance of a poorly soluble drug from a novel, Eudragit*-based multi-unit erosion matrix. Int J Pharm. 2001;213:7-12.